Anson Funds Management LP Sells 30,000 Shares of Pfizer Inc. $PFE

Key Points

• Anson Funds Management LP reduced its holdings in Pfizer Inc. by 25.0% in the 1st quarter, selling 30,000 shares and owning a total of 90,000 shares worth approximately $2.281 million.
• Several hedge funds have increased their positions in Pfizer, with Gould Capital LLC boosting its stake by 97.2% and multiple funds acquiring new positions together valued around $27,000 to $30,000.
• Pfizer reported earnings of $0.78 per share, exceeding consensus estimates, with quarterly revenue of $14.65 billion, marking a 10.3% increase from the previous year.

Anson Funds Management LP trimmed its position in Pfizer Inc. (NYSE:PFE - Free Report) by 25.0% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 90,000 shares of the biopharmaceutical company's stock after selling 30,000 shares during the period. Anson Funds Management LP's holdings in Pfizer were worth $2,281,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Gould Capital LLC raised its holdings in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $27,000. North Capital Inc. bought a new stake in shares of Pfizer during the first quarter worth approximately $28,000. Bayforest Capital Ltd acquired a new position in Pfizer in the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer in the fourth quarter valued at approximately $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PFE. Berenberg Bank cut their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Morgan Stanley increased their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. HSBC lowered their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Finally, Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Stock Down 3.8%

PFE stock traded down $0.95 during midday trading on Friday, hitting $23.91. The company's stock had a trading volume of 81,158,118 shares, compared to its average volume of 34,996,196. The company's fifty day moving average price is $24.79 and its 200 day moving average price is $24.30. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a market capitalization of $135.94 billion, a P/E ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter last year, the company earned $0.60 EPS. Pfizer's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.